FILER: ATLAS VENTURE FUND VII, LP - SUBJECT COMPANY: ARCA BIOPHARMA, INC.

Company

Oruka Therapeutics, Inc.

Filed

February 10, 2009

Accession Number

0000950135-09-000847

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →